CLYM
Climb Bio Inc
NASDAQ: CLYM · HEALTHCARE · BIOTECHNOLOGY
$14.25
-4.68% today
Updated 2026-09-11
Market cap
$818.47M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.82
Dividend yield
—
52W range
$2 – $18
Volume
1.3M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
10.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$27.57
+93.47%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy13 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 10.36 — safe zone
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-10.81M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-45.24M | $-35.12M | $-73.90M | $-59.85M | $-13.50M |
| EPS | — | — | — | — | $-0.82 |
| Free cash flow | $-37.37M | $-20.60M | $-15.56M | $-54.54M | $-10.81M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Climb Bio Inc trades at $14.25. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 10.36, it sits in the safe zone.
Frequently asked questions
What is Climb Bio Inc's stock price?
Climb Bio Inc (CLYM) trades at $14.25.
Is Climb Bio Inc overvalued?
Climb Bio Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Climb Bio Inc (CLYM)?
The 12-month analyst consensus target is $27.57, about 93.5% above the current $14.25. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Climb Bio Inc's Altman Z-Score is 10.36, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-24.06%
Beta0.10
50D MA$14.18
200D MA$8.97
Shares out0.06B
Float0.04B
Short ratio—
Avg volume1.3M
Performance
1 week-3.67%
1 month+3.89%
3 months+30.68%
YTD+273.75%
1 year—
3 years—
5 years—